<DOC>
	<DOCNO>NCT00717210</DOCNO>
	<brief_summary>Background : The optimal treatment anaplastic glioma controversial . Standard care center still radiotherapy . This phase III study compare efficacy safety radiotherapy v chemotherapy patient ( pt ) newly-diagnosed , supratentorial glioma WHO grade III . Methods : Pts randomize 2:1:1 June 1999 February 2005 34 German center receive ( ) 6-week course radiotherapy ( 1,8-2 Gy fraction , total dose 54-60 Gy ) ( ii ) four 6-week cycle CCNU 110 mg mg/m2 day 1 , vincristine 2 mg day 8 29 procarbazine 60 mg/m2 day 8-21 eight 4-week cycle 200 mg/m2 temozolomide day 1-5 . Treatment stop prematurely disease progression occurrence unacceptable toxicity . At time disease progression , treatment radiotherapy group continue one chemotherapy ( 1:1 randomization ) radiotherapy chemotherapy group . The primary endpoint time-to-treatment-failure ( TTF ) define progression radiotherapy one chemotherapy either sequence , time therapy could employ . Assuming 50 % improvement TTF start chemotherapy , 318 pt enrol provide 80 % power achieve statistical significance one-sided level 0.05 .</brief_summary>
	<brief_title>Randomized Phase III Study Sequential Radiochemotherapy Anaplastic Glioma With PCV Temozolomide</brief_title>
	<detailed_description />
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>write informed consent centrally confirm anaplastic glioma accord WHOclassification 1998/2000 age â‰¥ 18 year Karnofsky performance status ( KPS ) 70 high prior systemic chemotherapy radiation therapy brain HIV infection adequate bone marrow reserve , liver function , renal function Patients corticosteroid stable decrease dosage within 14 day prior randomization Glioblastoma infratentorial localization tumor pregnancy lactation period serious medical neurological comorbidity additional malignancy require radio chemotherapy know hypersensitivity study drug inability swallow frequent emesis psychological . familial , sociological geographical situation impair compliance F/U examination parallel participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>1p/19q loss</keyword>
	<keyword>MGMT</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>PCV</keyword>
	<keyword>temozolomide</keyword>
</DOC>